

重磅研究一览

2024美国临床肿瘤学会年会
淋巴瘤和慢性淋巴细胞白血病亮点抢先看

口头摘要专场

LBA7000	Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSg HD21, a randomized study. BrECADD与BEACOPP治疗晚期经典霍奇金淋巴瘤的耐受性和疗效: GHSg HD21, 一项随机研究。	Peter Borchmann (德国科隆大学亚琛波恩科隆 杜塞尔多夫综合肿瘤中心)
7001	Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial. 未经治疗的侵袭性ATL强化化疗后的先期allo-HSCT研究: JCOG0907, 一项单臂III期试验。	Takuya Fukushima (琉球大学医学部)
7002	CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/ T-cell lymphoma. CLAMP研究: camrelizumab联合pegaspargase、依托泊苷和高剂量甲氨蝶呤治疗自然杀伤(NK)/ T细胞淋巴瘤的II期前瞻性研究。	刘涛 教授 (华中科技大学同济医学院 附属协和医院)
LBA7003	Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study. Tucidinostat联合R-CHOP治疗先前未治疗的MYC和BCL2双重表达的弥漫性大B细胞淋巴瘤: 来自III期DEB研究的中期分析。	赵维莅 教授 (上海交通大学医学院 附属瑞金医院)
7004	Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells. Armored huCART19-IL18在抗cd19 CAR - T细胞治疗后进展的复发/难治性淋巴瘤患者中的安全性和有效性研究。	Jakub Svoboda (宾夕法尼亚医学中心 Abramson艾布拉姆森 癌症中心)
LBA7005	Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. Brentuximab vedotin联合来那度胺和利妥昔单抗治疗复发/难治性弥漫性大B细胞淋巴瘤患者: ECHELON-III期研究结果。	Jeong A Kim (圣文森特医院)
7006	Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma. 苯达莫司汀-利妥昔单抗一线治疗套细胞淋巴瘤后继续使用利妥昔单抗治疗的益处。	Yucai Wang (梅奥诊所)
7007	Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. SYMPATICO研究中伊布替尼联合venetoclax治疗套细胞淋巴瘤(MCL)和TP53突变患者的疗效和安全性研究。	Michael Wang (MD安德森癌症中心)
7008	Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study. Glofitamab单药治疗重度复发/难治性(R/R)套细胞淋巴瘤(MCL)患者: 来自I/II期研究的最新分析。	Tyrel Jovelle Phillips (希望之城国家医疗中心)

快速口头摘要专场

7009	Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. 固定疗程的伊布替尼+venetoclax治疗慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)后高危亚组的结果: II期验证研究中长达5.5年的随访。	William G. Wierda (MD安德森癌症中心)
7010	Real-world outcomes of lisocabtagene maraleucl (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). 来自国际血液和骨髓移植研究中心(CIBMTR)的Richter转化(RT)患者(pt)使用lisocabtagene maraleucl (liso- cel)的真实世界结果	Allison Marie Winter (克利夫兰医学中心)
7011	Examining two hematologic precursors and their impact on incident lymphoid malignancies. 检测两种血液前体及其对淋巴细胞恶性肿瘤的影响	Nicholas J. Boddicker
7012	Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701. R-CHOP+/-venetoclax治疗先前未治疗的MYC/BCL2双表达弥漫性大B细胞淋巴瘤(DLBCL)疗效的随机II/III期研究: Alliance A051701。	Jeremy S. Abramson (麻省总医院)
7013	Lisocabtagene maraleucl (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. Lisocabtagene maraleucl (liso-cel) 与标准护理(SOC)联合挽救性化疗(CT), 继而自体干细胞移植(ASCT)作为R/R大B细胞淋巴瘤(LBCL)患者(pt)的二线(2L)治疗临床研究: 随机III期转化研究的3年随访(FU)。	Manali Kirtikumar Kamdar (科罗拉多大学癌症中心)
7014	Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7. Epcoritamab联合利妥昔单抗+来那度胺(R2)治疗先前未治疗的(1L)滤泡性淋巴瘤(FL)和Epcoritamab维持治疗FL: EPCORE NHL-2第6和第7组。	Joshua D. Brody (西奈山伊坎医学院)
7015	EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL. EPCORE NHL - 1滤泡性淋巴瘤(FL)周期(C)1优化(OPT)队列: 扩大epcoritamab在复发或难治性(R/R)FL中的临床应用。	Julie Vose (内布拉斯加大学医学中心)
7016	Lisocabtagene maraleucl (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL). R/R套细胞淋巴瘤(MCL)患者(pt)的Lisocabtagene maraleucl (liso- cel): 根据TRANSCEND NHL 001 MCL队列(transcen -MCL)的既往全身治疗线(LOT)数量和对既往布鲁顿酪氨酸激酶抑制剂(BTKi)的反应进行亚组分析。	Maria Lia Palomba (纪念斯隆-凯特琳癌症中心)
7017	Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity. Timdarpacept (IMM01) 联合tislelizumab治疗既往抗PD-1失败的经典霍奇金淋巴瘤: 一项开放标签、多中心、II期研究(IMM01-04), 评估安全性和初步抗肿瘤活性。	Zhenjiu Wang

参考文献

2024 ASCO Meeting. Available online: <https://society.asco.org/meetings-education/meetings> (Access on 26th, Apr.2024)

审批号:

到期日:

仅供医疗卫生专业人士阅读/参考, 日程源于大会官网, 一切以官网信息为准。

标题: 淋巴瘤和慢性淋巴细胞白血病
重磅研究一览